MetaMedical™ Solutions Inc

Enovis sees highest patent filings and grants during August in Q3 2023

Enovis has been focused on protecting inventions in United States(US) with 38 publications in Q3 2023

The United States(US) Patent Office dominates the patent filings and grants with nearly 56% filings and 58% grants. The United States(US), World Intellectual Property Organization (WO), European Patent Office (EP), and Australia(AU) patent Office are among the top ten patent offices where Enovis is filings its patents. Among the top granted patent authorities, Enovis has 58% of its grants in United States(US), 18% in European Patent Office (EP), and 18% in Canada(CA).

Lincoln Electric could be the strongest competitor for Enovis

In terms of grant share, Enovis stands in second position among its competitors. Lincoln Electric and Illinois Tool Works secured the top positions according to recent patent publication data.

Access the most comprehensive Company Profiles
on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free

Your download email will arrive shortly

We are confident about the
quality of our Company Profiles. However, we want you to make the most
decision for your business, so we offer a free sample that you can download by
submitting the below form

By GlobalData

Patents related to climate change and healthtech lead Enovis’s portfolio

Enovis has the highest number of patents in climate change followed by, healthtech and electronic medical record (emr) systems. For climate change, nearly 30% of patents were filed and 0% of patents were granted in Q3 2023.

Orthopedic devices related patents lead Enovis portfolio followed by other remote patient monitoring, and general surgery devices

Enovis has highest number of patents in orthopedic devices followed by other remote patient monitoring, general surgery devices, energy infrastructure and manufacturing/industrial. For orthopedic devices, nearly 25% of patents were filed and 19% of patents were granted in Q3 2023.

For comprehensive analysis of Enovis’s filings and grants, buy the databook here.

Source link